Abbott Laboratories reported strong second-quarter results for 2026, posting adjusted earnings per share of $1.31 against a consensus estimate of $1.28. The company's revenue reached $12.59 billion, representing a significant year-over-year increase of 13.0%. This performance highlights the resilience of Abbott's core business segments amidst...
Abbott Laboratories reported a strong second quarter ended July 16, 2026, with revenue reaching $12.59 billion, representing a 13.0 percent year-over-year increase. The company delivered adjusted earnings per share of $1.31, which beat the consensus estimate of $1.28 by $0.03. This performance was driven by...
AlTi Global Inc. significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 54.7% in the first quarter, selling 12,779 shares to hold a remaining position of 10,563 shares valued at $1.085 million. This move contrasts with several other institutional investors who increased their holdings during...
Abbott Laboratories (NYSE:ABT) saw significant institutional activity in the fourth quarter, highlighted by a massive position increase from J. Stern & Co. LLP, which added over 39 million shares to its stake, bringing total ownership to nearly $4.9 billion. Other notable investors including Norges Bank,...
Abbott Laboratories was ordered by a Cook County jury on Thursday evening to pay at least $53 million in compensatory damages in four separate cases involving Chicago-area babies who developed necrotizing enterocolitis (NEC) after consuming the company's formula for premature infants. After more than a...
A Missouri Court of Appeals for the Eastern District has upheld a jury verdict against Abbott Laboratories, ordering the pharmaceutical giant to pay $495 million in damages related to its Similac infant formula. This ruling reaffirms a previous decision where plaintiffs alleged that their infants...
Abbott Laboratories stock gained value on September 19, 2026, trading at USD 102.35 following a significant reduction in legal uncertainty regarding its infant formula business. The company agreed to a settlement of nearly USD 385 million related to a 2022 recall and plant shutdown, resolving...
Abbott Laboratories (NYSE: ABT) announced on March 23, 2026, that it has completed its acquisition of Exact Sciences. Following the completion of the deal, Exact Sciences became a wholly owned subsidiary of Abbott, and trading for Exact Sciences shares ceased on Nasdaq with March 20,...
Citi upgraded Intuitive Surgical (ISRG) to a Buy rating from Neutral while maintaining its Buy ratings on Stryker (SYK) and Abbott Laboratories (ABT), citing healthy fundamentals for the medical technology sector despite recent market volatility. The firm, led by analyst Joanne Wuensch, argues that Intuitive...
Abbott Laboratories reported strong financial results for the June quarter, trading at USD 102.35 on September 19, 2026. The company posted earnings per share of USD 1.31, which beat analyst estimates by USD 0.03. Revenue reached USD 12.59 billion, representing a significant year-over-year increase of...
Equities analysts have issued mixed signals regarding Abbott Laboratories (NYSE:ABT) ahead of its fiscal year 2026 earnings, with Erste Group Bank reducing its full-year EPS estimate to $5.47 from $5.48 and Raymond James Financial cutting its price target to $115. Conversely, JPMorgan Chase raised its...
Absher Wealth Management LLC significantly increased its position in Abbott Laboratories (NYSE:ABT) by 68.9% in the first quarter, purchasing an additional 135,846 shares to own a total of 333,127 shares valued at $34.2 million. This move makes ABT the fund's 10th largest holding, representing 4.0%...
Abbott Laboratories (ABT) is characterized as a strong buy due to its structural undervaluation and resilient fundamentals, despite recent negative price action. The stock currently trades at a 17.1% P/E ratio and a 35.1% sales multiple discount relative to peers. Discounted Cash Flow (DCF) fair...
Protesters and civil society groups in Lagos staged a demonstration at the residence of the U.S. Consul General on Tuesday, accusing Abbott Diagnostics of undermining an ongoing court case against Acouns Nigeria Limited regarding the Determine HIV 1/2 Test Kit. The demonstrators argue that Abbott...
MiniMed, the diabetes technology spinoff from Medtronic, announced significant product and partnership developments during its first earnings call following its March IPO. The company is expanding its collaboration with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems; Abbott recently...
MiniMed expanded its strategic partnership with Abbott to integrate the company's dual glucose-ketone sensors into its portfolio, following a prior collaboration that included the Instinct sensor. The new integration involves commercializing Abbott's Libre Duo and Libre Duo 10 Day sensors, which continuously measure both glucose...
Abbott Laboratories stock traded at EUR 88.67 in after-hours trading on September 29, 2026, representing a minor decline of 0.11 percent against the prior session's close of EUR 88.77. The reference price for the day was established at EUR 88.77, with current market quotes showing...
Abbott Laboratories (NYSE:ABT) reported strong second-quarter results with total sales increasing 13% to $12.59 billion and adjusted EPS rising 4% to $1.31. The company's Medical Devices segment, its largest business, grew 8.4% on a comparable basis, driven by double-digit growth in Electrophysiology and Rhythm Management....
Abbott Laboratories stock declined 2.32% to close at USD 101.09 on September 24, 2026, trading below its yearly high despite recent positive earnings data. The company's market capitalization stood at approximately USD 174.9 billion with a daily trading volume of over 6 million shares. Second-quarter...
Abbott Laboratories achieved a significant regulatory milestone with the FDA granting De Novo authorization for its Libre Duo, becoming the first company to clear a wearable device capable of continuously monitoring both glucose and ketone levels. This innovation targets an existing ecosystem of over 8...
